Roivant Sciences Ltd (ROIV)
| Sector: | Health Care |
| Super Investor Stats: | |
| Ownership count: | 3 |
| Ownership rank: | 299 |
| % of all portfolios: | 0.037% |
| Hold Price * : | $27.70 |
| Total insider Buys/Sells last 6 months: |
| Transactions | Total |
| Buys |
0 |
$0 |
| Sells |
68 |
$572,972,753 |
|
Portfolio Manager |
% of portfolio |
Recent activity |
Shares |
Value |
| ≡ |
David Einhorn - Greenlight Capital |
1.87 |
Add 4.03% |
2,152,669 |
59,629,000 |
| ≡ |
Viking Global Investors |
0.52 |
Add 3.25% |
6,652,448 |
184,273,000 |
| ≡ |
Lee Ainslie - Maverick Capital |
0.52 |
Buy |
1,626,940 |
45,066,000 |
Open Market Insider Buys
| Date Filed |
Reporting Name |
Relationship |
Trans. Date |
Shares |
Price $ |
Total Value $ |
| 18 Sep 2025 |
GLINE MATTHEW |
CEO |
18 Sep 2025 |
3,315 |
15.07 |
49,957 |
| 14 Nov 2022 |
DEXCEL PHARMA TECHNOLOGIES LTD. |
10% |
10 Nov 2022 |
4,000,000 |
5.00 |
20,000,000 |
* "Hold Price" is the last known price at which an investor still held a security. It is the closing price of the security as of the portfolio date (quarter end). This value is only provided when a security is owned by at least two investors. In the case of reporting dates being different, a weighted average price is calculated.
P = Preferred Stock